Streetbeat News

Products Services

DB

DSEEY

JPM

MUFG

SFTBF

Daiwa Securities Group has allowed nearly 9,000 employees in Japan to use AI-powered chatbot ChatGPT, aiming to streamline retail business and improve efficiency. Other financial institutions, such as Deutsche Bank, JP Morgan, Softbank Group, and Mitsubishi UFJ Financial Group, are also exploring AI applications.

Portfolio Pulse from Anusuya Lahiri

June 05, 2023 | 11:42 am

ATVI

MSFT

SONY

TCEHY

Sony plans to explore streaming game options and leverage its AI agent GT Sophy to enhance cloud gaming, but CEO Kenichiro Yoshida warns of latency and costly inefficiencies. Microsoft's $75 billion Activision Blizzard takeover deal has intensified the competition between the two companies.

Portfolio Pulse from Anusuya Lahiri

June 05, 2023 | 11:33 am

AAPL

The Apple Store is temporarily down ahead of the company's Worldwide Developers Conference (WWDC), fueling speculations about potential product announcements.

Portfolio Pulse from Charles Gross

June 05, 2023 | 11:23 am

NEO

NeoGenomics (NASDAQ:NEO) announced new data supporting its RaDaR assay for detecting molecular residual disease (MRD) and recurrence in high-risk HR+/HER2- breast cancer patients. The data comes from a retrospective analysis of the Phase 3 PENELOPE-B study presented at the 2023 ASCO Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:22 am

MNMD

Numinus Wellness announced that Cedar Clinical Research (CCR), a subsidiary of Numinus, has been selected as a top research site for MindMed's Phase 2b study evaluating MM-120. This partnership will advance the development of psychedelic-assisted therapies.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:18 am

LUCD

PAVM

Lucid Diagnostics has launched its EsoGuard Mobile Test Unit, a mobile testing platform for esophageal cancer and precancerous conditions. The unit aims to increase accessibility and convenience for patients.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:16 am

AKRO

Akero Therapeutics announced that its Phase 2b SYMMETRY Cohort D study met safety and tolerability endpoints. EFX was well tolerated with comparable results between EFX and placebo groups, and the tolerability profile was similar to previous BALANCED and HARMONY studies.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:12 am

AAPL

Ahead of Apple's WWDC 2023, analyst Ming-Chi Kuo from TF International Securities stated that investors are more interested in Apple's AI-related initiatives than its AR/VR headset. Kuo believes the headset's success could depend on its integration with AI and AI-generated content.

Portfolio Pulse from Ananya Gairola

June 05, 2023 | 11:12 am

FHTX

The FDA has lifted the clinical hold on Foghorn Therapeutics' Phase 1 study of FHD-286 in acute myelogenous leukemia and myelodysplastic syndrome. The company plans to commence Phase 1 study of FHD-286 plus decitabine or cytarabine in relapsed/refractory AML in Q3 2023.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:12 am

BVXV

BiondVax has signed an exclusive worldwide license agreement to develop and commercialize a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, including psoriasis.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:11 am